Zhejiang Huahai Pharmaceutical (600521) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached RMB 5.13 billion, up 19.43% year-over-year; net profit attributable to shareholders was RMB 748.57 million, up 31.60% year-over-year.

• Growth driven by new product launches, expanded market coverage, and improved cost control.

• The company maintains a leading position in APIs and finished dosage forms, with global sales in 106 countries.

• R&D pipeline includes over 120 projects, with significant progress in innovative biologics and generics.

• No interim dividend or capital increase from reserves was proposed for the period.

Financial highlights

• Operating income: RMB 5.13 billion, up 19.43% year-over-year.

• Net profit attributable to shareholders: RMB 748.57 million, up 31.60% year-over-year.

• Operating cash flow: RMB 1.30 billion, up 45.72% year-over-year.

• Basic and diluted EPS: RMB 0.52, up 33.33% year-over-year.

• Gross margin improved due to product mix and cost optimization.

Outlook and guidance

• The company will continue to focus on international expansion, R&D innovation, and cost efficiency.

• Plans to accelerate the commercialization of new products and deepen global market penetration.

• Ongoing investment in advanced manufacturing and digital transformation to support long-term growth.